<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>2(11)</volume><submitter>Lipworth BJ</submitter><journal>The Lancet. Rheumatology</journal><pagination>e660</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7431124</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Tocilizumab for severe COVID-19 pneumonia.</pubmed_title><pmcid>PMC7431124</pmcid><pubmed_authors>Lipworth BJ</pubmed_authors><pubmed_authors>Kuo CR</pubmed_authors><pubmed_authors>Chan R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Tocilizumab for severe COVID-19 pneumonia.</name><description/><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-04-04T19:51:17.945Z</modification><creation>2025-04-04T19:51:17.945Z</creation></dates><accession>S-EPMC7431124</accession><cross_references><pubmed>32838325</pubmed><doi>10.1016/S2665-9913(20)30283-6</doi></cross_references></HashMap>